Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Enterprise Value (2016 - 2025)

IGC Pharma (IGC) has disclosed Enterprise Value for 16 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • Quarterly Enterprise Value rose 26.91% to -$1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Sep 2025, up 26.91% year-over-year, with the annual reading at -$405000.0 for FY2025, 66.19% up from the prior year.
  • Enterprise Value for Q3 2025 was -$1.1 million at IGC Pharma, down from -$454000.0 in the prior quarter.
  • The five-year high for Enterprise Value was -$405000.0 in Q1 2025, with the low at -$14.6 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$5.4 million, with a median of -$3.1 million recorded in 2023.
  • The sharpest move saw Enterprise Value plummeted 302.32% in 2021, then surged 75.79% in 2023.
  • Over 5 years, Enterprise Value stood at -$11.9 million in 2021, then skyrocketed by 57.85% to -$5.0 million in 2022, then soared by 72.62% to -$1.4 million in 2023, then surged by 65.89% to -$470000.0 in 2024, then crashed by 140.43% to -$1.1 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$1.1 million, -$454000.0, and -$405000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.